162 (Yangshengtang/Syneos Health)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Name162 (Yangshengtang/Syneos Health)
Drug Alias Nameanti-HBsAG antibody (Yangshentang/Syneos Health)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionHBsAg inhibitors
TargetsHepatitis B Surface Antigens
Therapy Area/IndicationsHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New Zealand
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesHainan Yangshengtang Phaymaceution Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSyneos Health IncHainan Yangshengtang Phaymaceution Co Ltd
Inactive CompaniesN/A
Active IndicationsHepatitis B
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A